To date, only two products have gained approval for the treatment of ASDs;
Risperdal (risperidone; Johnson & Johnson) and Abilify (aripiprazole;
Bristol-Myers Squibb/Otsuka Pharmaceuticals) are both approved in the US for
the treatment of irritability associated with autistic disorder.
Features and benefits
- Examination of key recommendations contained in published treatment
guidelines for the management of ASDs.
- Overview of the treatment pathway and identification of three key points
of influence that may be targeted by pharmaceutical companies.
- Discussion of key opportunities and threats facing existing and
prospective players in the autism spectrum disorders market.
ASDs are a complex spectrum of disorders, largely heterogeneous in etiology
and symptomatology. Increasing public awareness of the milder symptoms of the
disorders would serve to aid earlier recognition and presentation. In
addition, increasing physician education in relation to the use of validated
screening tools would aid earlier diagnosis.
Given that only two products are approved in the US for one of the behavioural
symptoms of ASDs, physicians largely rely on off-label prescribing for the
majority of symptoms. With few marketing strategies currently employed,
primary care physician detailing has the potential to boost product uptake in
the ASDs market.
Targeting the core symptoms of ASDs represents a "high-risk, high-reward"
strategy given the heterogeneity of patient presentation and unknown
etiologies, yet high population base. Meanwhile, the traditional route into
the ASDs market - targeting of individual symptoms - represents a "low-risk,
Your key questions answered
- What do current treatment guidelines recommend in relation to
pharmacological treatment of ASDs?
- What is the current typical treatment pathway for patients with ASDs?
Where are the key points of influence for market players?
- Which segment of the ASDs population offers the greatest commercial
potential to developers?
- What actions can pharmaceutical companies take in order to maximize the
uptake of products indicated for the treatment of ASDs?
- Which factors pose the greatest threat to the commercial potential of
products indicated for the treatment of ASDs?
Table of Contents
- Update details: April 2012
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
CASE STUDY IN AUTISM SPECTRUM DISORDERS
- Treatment guidelines for autism spectrum disorders
- Treatment should be individualized and systematically monitored
- Pharmacological treatment is considered an adjunct to behavioral and
- Published treatment guidelines are based on mixed clinical trial data
and focus on pediatric patients
- Treatment pathway
- First point of influence: increase public awareness in order to drive up
- Second point of influence: improved primary care physician education
will aid earlier diagnosis and intervention
- Third point of influence: physician detailing will boost product
- Opportunities and threats
- Despite increasing competition, growing industry interest will be
beneficial for new market entrants
- Key opportunities
- Key threats
- Journal papers
- Datamonitor reports
- Contributing experts
- Conferences attended
- Report methodology
- Table: Treatment recommendations for behavioral symptoms of autism
spectrum disorders from a selection of guidelines, 2012
- Table: Summary of key opportunities and threats within the autism spectrum
disorders market, 2011
- Figure: Autism spectrum disorder patient care pathway in the seven major
- Figure: Comparison of incentives conferred by orphan product policies
across the US, EU, and Japan, 2012
Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth published by Datamonitor in April 16, 2012. This report consists of Pages: 36 and the price starts from US $ 1900.
The contents of this page may be different from the latest version. Please contact us for details.